CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.12 by 125 percent. This is a 58.82 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $50.92 million which beat the analyst consensus estimate of $30.84 million by 65.11 percent. This is a 22.80 percent increase over sales of $41.46 million the same period last year.